IDH2 and intrahepatic cholangiocarcinoma: In the same model, mutant IDH and activated Kras (genetic alterations observed in a subset of human intrahepatic cholangiocarcinomas) drives expansion of liver progenitor cells, development of premalignant biliary lesions, and progression to metastatic intrahepatic cholangiocarcinomas [9].